about
Harnessing the immune system to improve cancer therapyEndogenous Antigen Presentation of MHC Class II Epitopes through Non-Autophagic PathwaysHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyImmunotherapy for Bone and Soft Tissue SarcomasEnhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE)A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapyT-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyGenome-wide analysis of cancer/testis gene expression.Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyRecent advances in treatment of advanced urothelial carcinoma.Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanomaMelanoma: tumor microenvironment and new treatments.Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancerNY-ESO-1 expression in DCIS: A new predictor of good prognosis.Seromic profiling of ovarian and pancreatic cancer.Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionPathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines.Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma.Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity.Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigensMeasurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer.Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity.Clinical validation of an autoantibody test for lung cancer.CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitHeteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cellsTertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabPolymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivoTrypanosoma cruzi as an effective cancer antigen delivery vector.Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancerRapid generation of NY-ESO-1-specific CD4(+) THELPER1 cells for adoptive T-cell therapy.
P2860
Q26738698-28463371-CF02-4D30-89D5-D3A5908F0EC8Q26781304-38676B44-2176-44A4-9AF7-26F3DB329E84Q27021570-94038734-CC2D-4E04-BA11-2985314B7ABCQ28088363-055F88E2-71D1-43A4-B7CC-B82B7FC87E0BQ28476101-F5C2C068-61EB-4B05-BC01-A42356BC6E58Q28709361-F6F80599-BB15-4419-B3E1-9BE9EA54C963Q30251555-62455091-D4A3-4C68-8355-1DA813C99B1CQ30299957-7D24D83F-43FC-4F8A-9467-D8BC75A91B11Q30438965-C1CFAAE0-4BA2-427A-B25A-5ED05299BB9DQ33393581-52B5B79E-C72C-4B79-9552-394F756539DEQ33522281-B33C95B7-E7C3-45FA-AA83-8FDDF9A908BFQ33565845-3C1C4B5D-1F4D-4C5D-9467-3505BB44397BQ33606137-07C6AE60-495C-4F33-B927-70F2387CF9B1Q33675676-1598C3EE-615E-4BD9-898B-107EC556209DQ33715446-0F1E86F2-D32B-43F0-9AE0-27A433399CA1Q33718676-0E7EF673-37B1-433B-9835-C4FFE4946E1EQ33739967-E613CA42-292F-4ABE-B5F0-1EA368D4FE3FQ33841896-1F756163-D247-4586-A934-A69950FCDDD0Q33909195-21458DEE-3D32-4258-8924-474B4BB45A4AQ33931434-01ACA650-E234-4B96-BE4E-6941E52110A4Q33941999-DB801DD5-BCFB-45F3-979A-8F093FDA7D89Q33967422-56D1334F-268C-4772-81EC-98C3CCCE4442Q34093600-B697B74C-68B3-48BB-BB2F-BEB4F248B0C1Q34111757-B008093E-BF4E-415A-96A7-112009A97DD2Q34111830-3C75B7F7-144D-40D1-8327-8CA9F6EF315EQ34111868-542FB29B-4C45-418D-9F19-BA16726022CCQ34119630-4A332B6A-37B5-4DE4-939E-C82971149C68Q34476665-623D0C66-3FE1-4E63-AB3F-0F42618B7C4FQ34537374-29E72D62-7109-4A09-9C96-D88416B73DBEQ34601772-8632E872-7579-42E8-B645-436E17EBF723Q34627677-6BB851E6-58DA-401B-AFD7-B1B8FDE5B0D5Q34795079-020D132D-C22D-48EB-82AD-F25A5E48D89CQ35067995-EE1992EB-534B-4B4E-89AD-69FF2A57C5B3Q35110486-EF404CD2-7772-40B8-8F90-269186909717Q35289145-0B864CFF-AF8D-47D5-94C0-B2206881E931Q35423276-DE079AB2-538D-4804-B53F-BD38D48D1BE5Q35621200-0AE99FF9-3C10-48D0-8ED0-9C7E00663CD8Q35733359-153951EA-E2A9-4372-956C-6156FD5983FBQ35782660-BE5FFBB7-E812-4DFC-844B-9EE7B8CDA246Q35799353-3AD7CF6A-6F1E-4288-8064-57CCD1C3B3E6
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
NY-ESO-1: review of an immunogenic tumor antigen.
@ast
NY-ESO-1: review of an immunogenic tumor antigen.
@en
NY-ESO-1: review of an immunogenic tumor antigen.
@nl
type
label
NY-ESO-1: review of an immunogenic tumor antigen.
@ast
NY-ESO-1: review of an immunogenic tumor antigen.
@en
NY-ESO-1: review of an immunogenic tumor antigen.
@nl
prefLabel
NY-ESO-1: review of an immunogenic tumor antigen.
@ast
NY-ESO-1: review of an immunogenic tumor antigen.
@en
NY-ESO-1: review of an immunogenic tumor antigen.
@nl
P2093
P1476
NY-ESO-1: review of an immunogenic tumor antigen.
@en
P2093
Achim A Jungbluth
Alexander Knuth
Ali O Güre
Elke Jäger
Gerd Ritter
Hiroyoshi Nishikawa
Lloyd J Old
Sacha Gnjatic
Yao-Tseng Chen
P356
10.1016/S0065-230X(06)95001-5
P577
2006-01-01T00:00:00Z